Clémentine R.
- Country
- France
- Department
- Médecine interne
Research Overview
- PREP-ANCA: Randomized Trial of Pre‑emptive Rituximab Versus Clinic‑Biological Surveillance for ANCA Re‑positivation in GPA and MPA Patients in Remission
- Phase II Study of Obinutuzumab in Patients with Systemic Lupus Erythematosus Pure Membranous Nephropathy (Class V Lupus Nephritis)
- Evaluation of Rituximab-Based Combination, Tocilizumab, and Tofacitinib in Granulomatosis with Polyangiitis Patients Unresponsive to Standard Therapy
Data & Insights
Has run more than one trial at 33 of 50 partner sites.
Specializations
ANCA-associated vasculitis and systemic inflammatory disease
The clinical research profile includes granulomatosis with polyangiitis, microscopic polyangiitis, eosinophilic granulomatosis with polyangiitis, and cryoglobulinemic vasculitis, with a strong therapeutic interest in remission induction, relapse prevention, and treatment in refractory disease.
- Rituximab
- Obinutuzumab
- Tocilizumab
- Avacopan
- Glucocorticoid-sparing therapy
Additional activity extends to giant cell arteritis and systemic sclerosis, reflecting a focus on immune-mediated vascular and connective tissue disorders.
Kidney diseases and nephroprotection
Research involvement covers IgA nephropathy, membranous nephropathy, focal segmental glomerulosclerosis, minimal change nephrotic syndrome, and rapidly progressive glomerulonephritis, with attention to preserving renal function and limiting proteinuria.
- Proteinuria reduction
- Renal function preservation
- End-stage renal disease
- Nephrotic syndrome
- Chronic kidney disease
The therapeutic landscape also includes lupus nephritis, ANCA-associated renal vasculitis, and kidney complications in critically ill patients.
Hematologic malignancies and cellular therapy
The investigator is engaged in studies of acute lymphoblastic leukemia, acute myeloid leukemia, follicular lymphoma, and peripheral T-cell lymphoma, with interest in modern immunotherapy and post-remission strategies.
- Blinatumomab
- Isatuximab
- Mosunetuzumab
- Lenalidomide
- Autologous stem cell transplantation
These activities are centered on improving disease control in younger adults and on refining treatment options for aggressive and relapsed blood cancers.
Solid tumors and precision oncology
Clinical trial involvement spans prostate cancer, colorectal cancer, pancreatic adenocarcinoma, and ROS1-positive non-small cell lung cancer, with an emphasis on targeted and biomarker-informed treatment approaches.
- Androgen receptor pathway inhibition
- Checkpoint inhibition
- ctDNA-guided treatment
- Anti-angiogenic therapy
- Molecularly selected therapy
The portfolio also includes metastatic colorectal cancer and pancreatic cancer, supporting interest in treatment optimization for advanced gastrointestinal malignancies.
Critical care, cardiovascular, and infectious disease care
Research activity includes septic shock, critical illness-related corticosteroid insufficiency, atrial fibrillation, stroke prevention, and coronary artery disease, alongside selected infectious and perioperative conditions.
- Hemodynamic support
- Anticoagulation
- Bleeding risk management
- Hypertension in chronic kidney disease
- Early syphilis
Additional interests include pleural infection, pneumothorax, and acute care outcomes in hospitalized patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.